Yao, H; Xie, SW; Ma, XQ; Liu, JK; Wu, HY; Lin, AJ; Yao, HQ; Li, DH; Xu, ST; Yang, DH; Chen, ZS; Xu, JY in [Yao, Hong; Xie, Shaowen; Ma, Xiaoqian; Liu, Junkai; Wu, Hongyu; Lin, Aijun; Yao, Hequan; Xu, Shengtao; Xu, Jinyi] China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R China; [Yao, Hong; Xie, Shaowen; Ma, Xiaoqian; Liu, Junkai; Wu, Hongyu; Lin, Aijun; Yao, Hequan; Xu, Shengtao; Xu, Jinyi] China Pharmaceut Univ, Dept Med Chem, Nanjing 210009, Peoples R China; [Li, Dahong] Shenyang Pharmaceut Univ, Sch Tradit Chinese Mat Med, Key Lab Struct Based Drug Design & Discovery, Minist Educ, Shenyang 110016, Peoples R China; [Yang, Dong-Hua; Chen, Zhe-Sheng] St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY 11439 USA published Identification of a Potent Oridonin Analogue for Treatment of Triple-Negative Breast Cancer in 2020, Cited 46. COA of Formula: C5H4N2O2. The Name is Pyrazine-2-carboxylic acid. Through research, I have a further understanding and discovery of 98-97-5.
Triple-negative breast cancer (TNBC) is one of the most highly invasive and metastatic breast cancers without safe and effective therapeutic drugs. The natural product oridonin is reported to be a potential anti-TNBC agent. However, its moderate activity and complex structure hampered its clinical application. In this study, the novel oridonin analogues were first identified by removal of multiple hydroxyl groups and structural simplification of oridonin. The representative analogue 20 exhibited potent anticancer effects. Further structural modification on 20 generated the most potent derivative 56, which possessed 120-fold more potent antiproliferative activity than oridonin in the TNBC cell line HCC1806. Importantly, compound 56 exhibited more potent anticancer activity than paclitaxel in TNBC xenograft nude mice. Moreover, 56 could attenuate the expression of MMP-2, MMP-9, p-FAK, and integrin beta 1 to inhibit TNBC cell metastasis. All results suggest that compound 56 may warrant further investigation as a promising candidate agent for the treatment of TNBC.
Welcome to talk about 98-97-5, If you have any questions, you can contact Yao, H; Xie, SW; Ma, XQ; Liu, JK; Wu, HY; Lin, AJ; Yao, HQ; Li, DH; Xu, ST; Yang, DH; Chen, ZS; Xu, JY or send Email.. COA of Formula: C5H4N2O2
Reference:
Patent; Chevron Research Company; US4732894; (1988); A;,
Pyrazine – Wikipedia,
Pyrazine | C4H4N2 – PubChem